We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer (PRIMM)

This study has been terminated.
(Recruitment difficulties)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01715363
First Posted: October 26, 2012
Last Update Posted: February 10, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris
  Purpose
The purpose of this study is to analyze the clinical tolerance of immediate preoperative chemotherapy in terms of toxicity and perioperative morbidity and mortality

Condition Intervention Phase
Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated Drug: Oxaliplatin Drug: Folinic Acid Drug: Fluorouracile Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency

Resource links provided by NLM:


Further study details as provided by Gustave Roussy, Cancer Campus, Grand Paris:

Primary Outcome Measures:
  • Clinical tolerance of immediate preoperative chemotherapy [ Time Frame: Assess up to 30 days after surgery ]

    Clinical tolerance of immediate preoperative chemotherapy assessment is based on the post-operative complication rate in terms of morbidity and mortality.

    All the post-operative complications arising within 30 days after surgery will be registered and classified using the Clavien Dindo classification



Enrollment: 3
Study Start Date: July 2012
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FOLFOX + surgery + FOLFOX
  • Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery
  • resection of the colorectal tumor during surgery
  • Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)
Drug: Oxaliplatin Drug: Folinic Acid Drug: Fluorouracile

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and visibles secondary lesions
  • primitive tumor must be operate
  • patient age between 18 and 70
  • OMS status performance < 2
  • life expectancy > 12 weeks
  • hematologic function : PNN >/= 1.5x10^9/L, platelets >/= 100x10^9/L
  • hepatic function : bilirubin </= 1.5xLSN, AST and ALT </= 3xLSN, alcalin phosphatasis </= 3xLSN
  • plasmatimic creatin </= 1.25xLSN
  • No previous chemotherapy or pelvic radiotherapy
  • men and women in age of procreate agreeing to use a contraception until 4 months after the end of treatment for women and until 6 months for men

Exclusion Criteria:

  • nonmetastatic forms
  • Colorectal tumor which requires preoperative radiotherapy
  • nonmeasurable metastasis based on RECIST criteria
  • previous chemotherapy for colorectal cancer
  • previous irradiation of the primitive tumour
  • specific indication against the treatment studied
  • Patient considered as inoperable for physiological or carcinologic reasons
  • Pregnant or breast feeding women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01715363


Locations
France
Institut Gustave Roussy
Villejuif, Val de Marne, France, 94805
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Investigators
Principal Investigator: Diane GOERE, MD Gustave Roussy, Cancer Campus, Grand Paris
  More Information

Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT01715363     History of Changes
Other Study ID Numbers: 2011-003446-41
2010/1676 ( Other Identifier: Institut Gustave Roussy )
First Submitted: October 24, 2012
First Posted: October 26, 2012
Last Update Posted: February 10, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Oxaliplatin
Leucovorin
Levoleucovorin
Folic Acid
Antineoplastic Agents
Antidotes
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Hematinics


To Top